Patent: 9,592,226
✉ Email this page to a colleague
Summary for Patent: 9,592,226
Title: | Solenopsin and derivatives, therapeutic compositions; and methods related thereto |
Abstract: | This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: ##STR00001## or salts, esters or prodrugs thereof as described herein. |
Inventor(s): | Arbiser; Jack L. (Atlanta, GA), Bowen; J. Philip (Atlanta, GA), Watkins; E. Blake (Jackson, TN) |
Assignee: | Emory University (Atlanta, GA) Mercer University (Atlanta, GA) Union University (Jackson, TN) |
Application Number: | 14/794,094 |
Patent Claims: | see list of patent claims |
Details for Patent 9,592,226
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-05-07 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-05-07 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2033-05-07 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2033-05-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |